Coronavirus Disease 2019 (COVID-19) Pharmacologic Treatments for Children: Research Priorities and Approach to Pediatric Studies

Anthony J. Garcia-Prats, Nicole Salazar-Austin, James H. Conway, Kendra Radtke, Sylvia M. Lacourse, Elizabeth Maleche-Obimbo, Anneke C. Hesseling, Rada M. Savic, Sharon Nachman

Research output: Contribution to journalReview articlepeer-review

Abstract

Clinical trials of pharmacologic treatments of coronavirus disease 2019 (COVID-19) are being rapidly designed and implemented in adults. Children are often not considered during development of novel treatments for infectious diseases until very late. Although children appear to have a lower risk compared with adults of severe COVID-19 disease, a substantial number of children globally will benefit from pharmacologic treatments. It will be reasonable to extrapolate efficacy of most treatments from adult trials to children. Pediatric trials should focus on characterizing a treatment's pharmacokinetics, optimal dose, and safety across the age spectrum. These trials should use an adaptive design to efficiently add or remove arms in what will be a rapidly evolving treatment landscape, and should involve a large number of sites across the globe in a collaborative effort to facilitate efficient implementation. All stakeholders must commit to equitable access to any effective, safe treatment for children everywhere.

Original languageEnglish (US)
Pages (from-to)1067-1073
Number of pages7
JournalClinical Infectious Diseases
Volume72
Issue number6
DOIs
StatePublished - Mar 15 2021

Keywords

  • COVID-19
  • children
  • pharmacokinetics
  • research
  • trials

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Coronavirus Disease 2019 (COVID-19) Pharmacologic Treatments for Children: Research Priorities and Approach to Pediatric Studies'. Together they form a unique fingerprint.

Cite this